Publishing Service

Polishing & Checking

Journal of Zhejiang University SCIENCE B

ISSN 1673-1581(Print), 1862-1783(Online), Monthly

Macrophage-produced IL-10 limits the chemotherapy efficacy in breast cancer

Abstract: Macrophages are among the most abundant immune cells in the tumor microenvironment, where they are known as tumor-associated macrophages (TAMs). Substantial evidence indicates that TAMs generally play protumoral roles in the primary as well as metastatic sites (Noy and Pollard, 2014). TAMs are also known to interfere with several tumor therapeutic modalities, such as chemotherapy, irradiation, and immunotherapy. In general, depletion of M2-like TAMs or reprogramming them into M1-like phenotype enhances the efficacy of these therapies (Rolny et al., 2011; de Palma and Lewis, 2013; Germano et al., 2013).

Key words: Breast cancer, Chemotherapy, Macrophage, IL-10, IL-12, Dendritic cell

Chinese Summary  <35> 巨噬细胞产生的白介素-10降低乳腺癌的化疗疗效

概要:本文简单介绍了最近发表在《肿瘤细胞》(Cancer Cell)上的一篇关于如何提高乳腺癌化疗疗效的文章。这篇文章发现了乳腺癌化疗可以导致促肿瘤生长的巨噬细胞数量的增多,这些巨噬细胞可以产生大量的白介素-10(IL-10),从而抑制肿瘤内树突状细胞IL-12的产生,由此抑制具细胞毒性的CD8+ T细胞的功能,最终降低化疗疗效。除此之外,文章还证明了阻断IL-10的功能可以促进乳腺癌化疗效果。这篇文章因此提出了可以降低乳腺癌化疗耐受的一种新的治疗靶点。

关键词组:乳腺癌;化疗;巨噬细胞;IL-10;IL-12;树突状细胞


Share this article to: More

Go to Contents

References:

<Show All>

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





DOI:

10.1631/jzus.B1400352

CLC number:

Download Full Text:

Click Here

Downloaded:

2602

Clicked:

5065

Cited:

3

On-line Access:

2024-08-27

Received:

2023-10-17

Revision Accepted:

2024-05-08

Crosschecked:

Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952276; Fax: +86-571-87952331; E-mail: jzus@zju.edu.cn
Copyright © 2000~ Journal of Zhejiang University-SCIENCE